Sanofi, aiming to speed MS treatment, to acquire Principia Biopharma
Sanofi announced this morning that it would acquire South San Francisco biotech Principia Biopharma for $3.68 billion.
The deal, which values Principia at $100 per share, will give the French drug giant full control over the multiple sclerosis treatment the companies share. But the deal also gives Sanofi several other BTK inhibitors — short for Bruton’s kinase inhibitors — that Principia has been developing for other diseases.
“Principia’s successful design and development of a whole portfolio of BTK inhibitors for immunology is aimed to transform the treatment for patients with immune-mediated diseases,” the company’s CEO, Martin Babler, said in a statement. “By combining with Sanofi, we will bring significant resources to expand and accelerate the potential benefits of these therapies.”
Read more.
The deal, which values Principia at $100 per share, will give the French drug giant full control over the multiple sclerosis treatment the companies share. But the deal also gives Sanofi several other BTK inhibitors — short for Bruton’s kinase inhibitors — that Principia has been developing for other diseases.
“Principia’s successful design and development of a whole portfolio of BTK inhibitors for immunology is aimed to transform the treatment for patients with immune-mediated diseases,” the company’s CEO, Martin Babler, said in a statement. “By combining with Sanofi, we will bring significant resources to expand and accelerate the potential benefits of these therapies.”
Read more.
.png)
No hay comentarios:
Publicar un comentario